United States Cellular Analyst Ratings
United States Cellular Analyst Ratings
| Date | Upside/Downside | Analyst Firm | Price Target Change | Rating Change | Previous / Current Rating |
|---|---|---|---|---|---|
| 08/09/2023 | 0.93% | Wells Fargo | $16 → $38 | Upgrades | Underweight → Equal-Weight |
| 08/08/2023 | — | JP Morgan | Upgrades | Neutral → Overweight | |
| 07/26/2023 | -28.29% | Morgan Stanley | $26 → $27 | Maintains | Equal-Weight |
| 07/25/2023 | -28.29% | Morgan Stanley | $26 → $27 | Maintains | Equal-Weight |
| 05/08/2023 | -57.5% | Wells Fargo | $22 → $16 | Maintains | Underweight |
| 02/07/2023 | -36.25% | Morgan Stanley | $37 → $24 | Maintains | Equal-Weight |
| 01/10/2023 | -46.88% | Wells Fargo | $33 → $20 | Downgrades | Overweight → Underweight |
| 11/08/2022 | -36.25% | JP Morgan | $32 → $24 | Upgrades | Underweight → Neutral |
| 11/07/2022 | — | Raymond James | Downgrades | Strong Buy → Market Perform | |
| 08/08/2022 | 3.59% | Raymond James | $41 → $39 | Maintains | Strong Buy |
| 05/09/2022 | 8.9% | Raymond James | $40 → $41 | Maintains | Strong Buy |
| 04/19/2022 | -1.73% | Morgan Stanley | → $37 | Downgrades | Overweight → Equal-Weight |
| 02/22/2022 | -12.35% | Wells Fargo | $36 → $33 | Maintains | Overweight |
| 02/22/2022 | 6.24% | Raymond James | $43 → $40 | Maintains | Strong Buy |
| 08/02/2021 | -4.38% | JP Morgan | $35 → $36 | Downgrades | Neutral → Underweight |
| 07/22/2021 | 32.8% | Morgan Stanley | $50.5 → $50 | Maintains | Overweight |
| 02/22/2021 | -7.04% | JP Morgan | $42 → $35 | Downgrades | Overweight → Neutral |
| 01/14/2021 | 34.13% | Morgan Stanley | $57 → $50.5 | Maintains | Overweight |
| 11/16/2020 | -4.38% | Wells Fargo | → $36 | Reinstates | → Overweight |
| 08/31/2020 | 22.18% | Citigroup | $45 → $46 | Maintains | Buy |
| 08/27/2020 | 51.39% | Morgan Stanley | $56 → $57 | Maintains | Overweight |
| 08/10/2020 | 14.21% | Raymond James | $40 → $43 | Maintains | Strong Buy |
| 07/08/2020 | 48.74% | Morgan Stanley | $57 → $56 | Maintains | Overweight |
| 05/18/2020 | 6.24% | Raymond James | $39 → $40 | Reiterates | → Strong Buy |
| 05/14/2020 | -9.69% | B. Riley Securities | $42 → $34 | Maintains | Neutral |
| 04/22/2020 | 3.59% | Raymond James | $41 → $39 | Maintains | Strong Buy |
| 04/09/2020 | 51.39% | Morgan Stanley | $63 → $57 | Maintains | Overweight |
| 03/27/2020 | 11.55% | JP Morgan | $45 → $42 | Maintains | Overweight |
| 03/02/2020 | 67.33% | Citigroup | $66 → $63 | Maintains | Buy |
| 11/04/2019 | 30.15% | Raymond James | $53 → $49 | Upgrades | Outperform → Strong Buy |
| 11/04/2019 | 19.52% | JP Morgan | → $45 | Upgrades | Neutral → Overweight |
| 08/06/2019 | 6.24% | Wells Fargo | $50 → $40 | Maintains | Market Perform |
| 08/06/2019 | 11.55% | B. Riley Securities | $50 → $42 | Maintains | Neutral |
| 08/05/2019 | 22.18% | JP Morgan | → $46 | Upgrades | Underweight → Neutral |
| 06/18/2019 | 71.31% | Morgan Stanley | $44 → $64.5 | Upgrades | Equal-Weight → Overweight |
| 05/06/2019 | 40.77% | Raymond James | $56 → $53 | Reiterates | → Outperform |
| 11/06/2018 | 48.74% | Raymond James | $43 → $56 | Maintains | Outperform |
| 日期 | 上行/下行 | 分析公司 | 目標價格變化 | 評級變化 | 上一次/當前評級 |
|---|---|---|---|---|---|
| 08/09/2023 | 0.93% | 富國銀行 | $16→$38 | 升級 | 重量不足的→等重 |
| 2023/08/08 | - | 摩根大通 | 升級 | 中性→超重 | |
| 07/26/2023 | -28.29% | 摩根士丹利 | $26→$27 | 維護 | 等重 |
| 07/25/2023 | -28.29% | 摩根士丹利 | $26→$27 | 維護 | 等重 |
| 05/08/2023 | -57.5% | 富國銀行 | $22→$16 | 維護 | 體重不足 |
| 02/07/2023 | -36.25% | 摩根士丹利 | $37→$24 | 維護 | 等重 |
| 2023年1月10日 | -46.88% | 富國銀行 | $33→$20 | 評級下調 | 增持→減持 |
| 11/08/2022 | -36.25% | 摩根大通 | $32→$24 | 升級 | 減重→中性 |
| 11/07/2022 | - | 雷蒙德·詹姆斯 | 評級下調 | 強勁的購買→市場表現 | |
| 2022/08/08 | 3.59% | 雷蒙德·詹姆斯 | $41→$39 | 維護 | 強勢購買 |
| 05/09/2022 | 8.9% | 雷蒙德·詹姆斯 | $40→$41 | 維護 | 強勢購買 |
| 04/19/2022 | -1.73% | 摩根士丹利 | →$37 | 評級下調 | 超重→等重 |
| 02/22/2022 | -12.35% | 富國銀行 | $36→$33 | 維護 | 超重 |
| 02/22/2022 | 6.24% | 雷蒙德·詹姆斯 | $43→$40 | 維護 | 強勢購買 |
| 08/02/2021 | -4.38% | 摩根大通 | $35→$36 | 評級下調 | 中性→減持 |
| 07/22/2021 | 32.8% | 摩根士丹利 | $50.5→$50 | 維護 | 超重 |
| 02/22/2021 | -7.04% | 摩根大通 | $42→$35 | 評級下調 | 超重→中性 |
| 2021/01/14 | 34.13% | 摩根士丹利 | $57→$50.5 | 維護 | 超重 |
| 11/16/2020 | -4.38% | 富國銀行 | →$36 | 恢復 | →超重 |
| 08/31/2020 | 22.18% | 花旗集團 | $45→$46 | 維護 | 買 |
| 2020/08/27 | 51.39% | 摩根士丹利 | $56→$57 | 維護 | 超重 |
| 2020/08/10 | 14.21% | 雷蒙德·詹姆斯 | $40→$43 | 維護 | 強勢購買 |
| 07/08/2020 | 48.74% | 摩根士丹利 | $57→$56 | 維護 | 超重 |
| 05/18/2020 | 6.24% | 雷蒙德·詹姆斯 | $39→$40 | 重申 | →強勢購買 |
| 2020/05/14 | -9.69% | B.萊利證券 | $42→$34 | 維護 | 中性 |
| 04/22/2020 | 3.59% | 雷蒙德·詹姆斯 | $41→$39 | 維護 | 強勢購買 |
| 04/09/2020 | 51.39% | 摩根士丹利 | $63→$57 | 維護 | 超重 |
| 03/27/2020 | 11.55% | 摩根大通 | $45→$42 | 維護 | 超重 |
| 03/02/2020 | 67.33% | 花旗集團 | $66→$63 | 維護 | 買 |
| 2019/11/04 | 30.15% | 雷蒙德·詹姆斯 | $53→$49 | 升級 | 跑贏→強勢買入 |
| 2019/11/04 | 19.52% | 摩根大通 | →$45 | 升級 | 中性→超重 |
| 2019年08月06日 | 6.24% | 富國銀行 | $50→$40 | 維護 | 市場表現 |
| 2019年08月06日 | 11.55% | B.萊利證券 | $50→$42 | 維護 | 中性 |
| 2019年08月05日 | 22.18% | 摩根大通 | →$46 | 升級 | 減重→中性 |
| 2019年06月18日 | 71.31% | 摩根士丹利 | $44→$64.5 | 升級 | 等重→超重 |
| 2019年05月06日 | 40.77% | 雷蒙德·詹姆斯 | $56→$53 | 重申 | →跑贏大盤 |
| 2018/06/11 | 48.74% | 雷蒙德·詹姆斯 | $43→$56 | 維護 | 跑贏大盤 |
What is the target price for United States Cellular (USM)?
美國蜂窩(USM)的目標價是多少？
The latest price target for United States Cellular (NYSE: USM) was reported by Wells Fargo on August 9, 2023. The analyst firm set a price target for $38.00 expecting USM to rise to within 12 months (a possible 0.93% upside). 9 analyst firms have reported ratings in the last year.
富國銀行於2023年8月9日報道了美國蜂窩(紐約證券交易所代碼：USM)的最新目標價。這家分析公司將目標價定為38.00美元，預計USM將在12個月內上漲至0.93%(可能上漲0.93%)。去年有9家分析公司公佈了評級。
What is the most recent analyst rating for United States Cellular (USM)?
美國蜂窩(USM)的最新分析師評級是多少？
The latest analyst rating for United States Cellular (NYSE: USM) was provided by Wells Fargo, and United States Cellular upgraded their equal-weight rating.
美國細胞公司(紐約證券交易所代碼：USM)的最新分析師評級由富國銀行提供，美國細胞公司上調了其同等權重的評級。
When is the next analyst rating going to be posted or updated for United States Cellular (USM)?
美國蜂窩(USM)的下一次分析師評級將於何時發佈或更新？
Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of United States Cellular, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for United States Cellular was filed on August 9, 2023 so you should expect the next rating to be made available sometime around August 9, 2024.
分析師在進行了廣泛的研究後得出了股票評級，這些研究包括查閱公共財務報表，與United States Ccell的高管和客戶交談，以及收聽收益電話會議。大多數分析師每三個月就會這樣做一次，所以你每年應該會得到每家公司每家公司的4個評級。美國蜂窩的上一次評級是在2023年8月9日提交的，所以你應該預計下一次評級將在2024年8月9日左右提供。
Is the Analyst Rating United States Cellular (USM) correct?
分析師對美國蜂窩(USM)的評級正確嗎？
While ratings are subjective and will change, the latest United States Cellular (USM) rating was a upgraded with a price target of $16.00 to $38.00. The current price United States Cellular (USM) is trading at is $37.65, which is within the analyst's predicted range.
雖然評級是主觀的，並將發生變化，但最新的美國蜂窩(USM)評級被上調，目標價為16.00美元至38.00美元。目前美國行動電話(USM)的交易價格為37.65美元，在分析師的預測範圍內。
譯文內容由第三人軟體翻譯。